The Uromigos

In this Uromigos podcast episode, Brian and Tom engage with Elaine Chang from the FDA to discuss an analysis of depth of response as an indicator of survival in kidney cancer trials. They explore the FDA's data analysis process, the significance of tumor shrinkage, and the implications of their findings on treatment outcomes. The conversation delves into the limitations of current measurement methods and the potential for using depth of response as an early signal in drug development.

In this episode of the Uromigos podcast, Brian Rini, Tom Powles, and Karine Tawagi discuss the complexities of immunotherapy re-challenge in bladder cancer. They explore the current landscape, including the challenges of existing data, the importance of understanding patient responses, and the potential for future research in antibody-drug conjugates (ADCs). The conversation highlights the need for more definitive studies to guide treatment decisions and improve patient outcomes.

In this podcast, the Brian, Tm and David Einstein discuss the EMBARK study and its implications for patients with biochemically relapsed prostate cancer. They explore the criteria for high-risk patients, the role of PSMA PET imaging, and the findings related to metastasis-free survival and overall survival. The conversation also delves into treatment strategies, adverse events, and patient perspectives on treatment decisions, ultimately highlighting the need for future research in this evolving field.

This podcast discusses the significance of variant histology in urothelial cancer, emphasizing the need for tailored treatment approaches based on histological features. Experts David Aggen, Tom Powles and Brian Rini explore various variant histologies, their implications for treatment, and the challenges in managing mixed histology tumors. The conversation highlights the importance of expert pathology reviews and the evolving landscape of neoadjuvant therapy in this field.

In this podcast, Brian and Tom engage with Pedro Barata to discuss the emerging field of bispecific T cell engagers and antibody-drug conjugates (ADCs) in the treatment of prostate cancer. They explore the promising data surrounding these therapies, the challenges faced in clinical trials, and the implications of phase three studies. The discussion also touches on the comparative development of ADCs in prostate cancer versus bladder cancer, highlighting the unique challenges and opportunities in each area. The conversation concludes with reflections on the future of these therapies and the potential for combination strategies to enhance treatment efficacy